CSL Behring
is a Pennsylvania-based biopharmaceutical company that develops protein-based therapies for the treatment of bleeding disorders and pulmonary disease... Read moreCSL Behring
is a Pennsylvania-based biopharmaceutical company that develops protein-based therapies for the treatment of bleeding disorders and pulmonary disease... Read more
News
Feb 12, 2025
PMLiVE
CSL Behring: CSL Behring announces four-year results for haemophilia B gene therapy Hemgenix
Nov 18, 2024
Endpoints News
CSL Behring: CSL Behring will close California office as part of shrinking ex vivo work
Jul 16, 2024
FinanzNachrichten
CSL Behring: CSL Behring Says HEMGENIX Receives Positive Canada Reimbursement Decision
Jul 04, 2024
GlobalNewswire
Press Release: CSL Behring : CSL Behring Announces First Two Patients Treated with HEMGENIX (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe
Mar 20, 2024
Medthority
CSL Behring: Ferinject (ferric carboxymaltose) approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
Jan 03, 2024
PR Newswire
Press Release: CSL Behring : CSL Behring Announces Availability of Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe
Jun 09, 2023
Owler
CSL Behring: CSL Behring's estimated revenue changed from $8.57B in May 2022 to $8.60B in Jun 2023
Apr 26, 2023
Medthority
CSL Behring: FDA approval for Hizentra (20% liquid) 50mL//10gm prefilled syringe to treat primary immunodeficiency and chronic inflammatory demyelinating polyneuropathy
Mar 27, 2023
PharmaTimes
CSL Behring: CSL's Hemgenix receives MHRA authorisation
Mar 20, 2023
cslbehring
Press Release: CSL Behring : CSL's Communications Function Recognized Among Top 5 Teams in the World
CSL Behring Competitors
1
2
3
4
5
6
7
8
9
10